Lifeline Biotechnologies Inc (LLBO)

[L_Rab]

$LLBO EXTENSIVE DD REPORT and HISTORY:


PRODUCT NAME: iTBraTM

MAJOR PARTNERS DEVELOPING/ HELPING TO DEVELOP PRODUCT: Cisco, Stanford University, and Flextronics (KEEP READING, LINKS WILL BE PROVIDED TO VALIDATE THESE PARTNERSHIPS!!)



Lifeline Biotechnologies Website Link: http://www.lbti.com/#!info/c4nz


1) In 2008, after filing a patent for it's First Warning™ System, Lifeline Biotechnologies (LLBO) formed it's wholly owned subsidary titled First Warning Systems, Inc.

Link to 2008 Press Release: http://www.businesswire.com/news/home/20080922005588/en/Lifeline-Biotechnologies-Forms-Warning-Systems-TM#.VQirI16LQds

"Launched in 2008, First Warning is not a typical start-up. It develops and markets licensed technologies from its parent company, Lifeline Biotechnologies. First Warning’s CEO, Rob Royea, has a rich history in the medical technology industry, previously serving as general manager for Siemens Medical’s ultrasound, PACS and catheter division in the U.S."

Read more at: http://www.business2community.com/mobile-apps/take-two-wearables-call-morning-mobile-making-us-healthier-0594870#cpXLJixGteOszH8Y.99

2) In 2012, LLBO Obtained 3 Patents for it's First Warning™ System

LINK to Press Release: http://www.prnewswire.com/news-releases/lifeline-biotechnologies-receives-third-software-patent-170071356.html

3) In September 2014, First Warning Systems Changes Name to Cyrcadia Health

LINK: http://cyrcadiahealth.com/first-warning-systems-changes-name-to-cyrcadia-health/

4) Business Partner with AMS (Advanced Medical System): http://www.amssg.com/AMS/PR_2014_files/CHI_Press%20Release_031014.pdf

5) Cyrcadia Health Website LINK: http://cyrcadiahealth.com/core-technology/


RECENT NEWS : http://finance.yahoo.com/news/lifeline-biotechnologies-llbo-q1-2015-171609507.html

LLBO History + Website LINK: http://www.lbti.com/#!info/c4nz

Quote From Afforementioned Press Release: :

" LLBO's primary asset is its investment in Cyrcadia Inc. (Cyrcadia). That investment is achieving meaningful added value as Cyrcadia prepares to enter the final clinical trials that will be conducted at El Camino Hospital (ECH) in Mountain View, CA and the Ohio State University (OSU) Oncology Hospital in Columbus, OH. The trials have been approved through Investigational Review Boards (IRB's) of ECH and are currently undergoing the review process at OSU. The ECH trial is slated for start before the end of April 2015. The trials are expected to be completed in four to 6 months. On completion Cyrcadia will obtain CE Marking allowing for sales and marketing outside of the USA. On completion of the trials Cyrcadia will be submitting a 510(k) to the FDA. Post clearance, marketing will begin in the USA. International sales are expected in Q4 of 2015 and US sales in Q1 or Q2 of 2016"


INDEPENDENT PRIMARY MARKET RESEARCH VALUATION AND EXECUTIVE SUMMARY MUST READ:

http://quoi.info/wp-content/uploads/2012/10/executive-summary.pdf


5) Stanford University Canary Center for Early Cancer Detection has pledged $187,000 to help fund the equipment for the trials at El Camino Hospital.

LINK To Press Release: http://www.otcmarkets.com/stock/LLBO/news/Lifeline-Biotechnologies--LLBO--Q1-2015-Update?id=99373&b=y



6 )Detected, a documentary movie about the journey to market of the iTBra™ was commissioned and paid for by Cisco Systems and will premiere at the SxSW Technology and Film Festival in Austin Texas next week, 3/16/15.

LINK TO AMAZING DETECTED TRAILER: http://newsroom.cisco.com/video-content?type=webcontent&articleId=1611072

LINK To Detected Movie Site: http://detectedmovie.com

7) CISCO is Promoting the Hell out of Cyrcadia and it's Breakthrough iTBra

CISCO YOUTUBE VIDEO:

LINK TO CISCO TWEETS ABOUT CIRCADIA AND THE MOVIE DETECTED (470K FOLLOWERS):

https://twitter.com/Cisco/status/577511348424167424
https://twitter.com/detectedmovie/status/577541555449364480
https://twitter.com/Cisco/status/577546373572239360



8) LINK TO CYRCADIA'S RESEARCH AND DEVELOPMENT TEAM FEATURNG TOP 1% SURGEON IN WORLD + STANFORD GRADS: cyrcadiahealth.com/medical-advisory-board/

CYRCADIA BREAST-CANCER PREVENTION DEVICE CLINICAL TRIAL RESULTS:

LINK: http://cyrcadiahealth.com/core-technology/

Over 500 women tested in previous clinical trials achieved promising results in sensitiy and accuracy at 87% correlation to cancer, when compared to mammography’s 83% correlation. The studies also indicated improved outcomes for the Cyrcadia Health solution in difficult to image (dense breast tissue) patient populations. Cyrcadia Health is preparing for a multi-site final validation clinical study to be conducted in leading US and Asia cancer hospitals in late 2014. Cyrcadia Health intends to show equal to improved results to mammography in the general population with improved results over todays “gold standards” in the dense tissue population, which entails over 60% of all women under, and 40% over the age of 40. Our comfortable, non-compressive and non-irradiative approach will help to populate a global “big data” core library on phenotype/genotype, and demographic variables contributing to the state of breast cancer on a worldwide basis.


MORE EFFECTIVE THAN THE MODERN DAY TREATMENT AND BENEFICIAL EARLY DETECTION ASPECT + COST EFFECTIVE

THE TECHNOLOGY SAVES CONSUMERS AND MEDICAL INSURANCES MONEY:

The Cyrcadia Health solution is a cost effective system that through early screening and detection can improve patient outcomes, reduce healthcare costs, improve surgical decision processes, and is a patient-friendly solution for breast screening.

Doctors Weigh in LINK: http://thedoctorweighsin.com/cyrcadia-health-wearable-social-breast-cancer-screening-bra/


9) FLEXTRONICS ($7BILLION DOLLAR COMPANY) IS INVESTED IN CYRCADIA'S REVOLUTIONARY PRODUCT AND IS MANUFACTURING THE ITBRA: https://gigaom.com/2015/02/10/heres-a-cancer-detecting-bra-thats-better-than-a-mammogram/



"The product looks like a sports bra and will eventually hold a grid-like mesh of sensors, manufactured by Flextronics, inside the fabric.

iTbra is getting a boost via a documentary film backed by Cisco, which will be shown at SXSW Film in Austin, Texas next month. Cisco is getting involved because it hopes to build a big business helping old-line companies understand how to bring technology into their day-to-day operations. "


CYRCADIA HEALTH SOLUTIONS PARTNERS LINK: http://cyrcadiahealth.com/partners/

FLEXTRONICS CEO INTERVIEW REVEALS IT ALL (SKIP TO 5:50 IF IN RUSH):

10) The ECH trial is slated for start before the end of April 2015.

The trials are expected to be completed in four to 6 months. On completion Cyrcadia will obtain CE Marking allowing for sales and marketing outside of the USA. On completion of the trials Cyrcadia will be submitting a 510(k) to the FDA. Post clearance, marketing will begin in the USA.

It is interesting to note that Dr. Farrar at OSU will be the primary investigator for the trials conducted at OSU. Dr. Farrar headed the original "proof of concept" study that was conducted at OSU. Dr. Farrar published on the results of this study, commenting on the potential of this lifesaving technology that could assist in the early detection of breast tissue abnormalities and breast cancers.

LINK TO AFFOREMENTIONED QUOTES: http://www.marketwired.com/press-release/lifeline-biotechnologies-llbo-q1-2015-update-otc-pink-llbo-1999978.htm

CYRCADIA HEALTH FEATURED ON ABC 7: http://cyrcadiahealth.com/abc-7-news-video/

OTC SHORT REPORT LINK : http://otcshortreport.com/index.php?index=LLBO#.VQeb5V6LQds

BARCHART TRADER'S CHEAT SHEET: http://www.barchart.com/cheatsheet.php?sym=LLBO

LLBO Share Structure: http://www.otcmarkets.com/stock/LLBO/profile

650m FLOAT


GLTA$LLBO EXTENSIVE DD REPORT and HISTORY:


PRODUCT NAME: iTBraTM

MAJOR PARTNERS DEVELOPING/ HELPING TO DEVELOP PRODUCT: Cisco, Stanford University, and Flextronics (KEEP READING, LINKS WILL BE PROVIDED TO VALIDATE THESE PARTNERSHIPS!!)



Lifeline Biotechnologies Website Link: http://www.lbti.com/#!info/c4nz


1) In 2008, after filing a patent for it's First Warning™ System, Lifeline Biotechnologies (LLBO) formed it's wholly owned subsidary titled First Warning Systems, Inc.

Link to 2008 Press Release: http://www.businesswire.com/news/home/20080922005588/en/Lifeline-Biotechnologies-Forms-Warning-Systems-TM#.VQirI16LQds

"Launched in 2008, First Warning is not a typical start-up. It develops and markets licensed technologies from its parent company, Lifeline Biotechnologies. First Warning’s CEO, Rob Royea, has a rich history in the medical technology industry, previously serving as general manager for Siemens Medical’s ultrasound, PACS and catheter division in the U.S."

Read more at: http://www.business2community.com/mobile-apps/take-two-wearables-call-morning-mobile-making-us-healthier-0594870#cpXLJixGteOszH8Y.99

2) In 2012, LLBO Obtained 3 Patents for it's First Warning™ System

LINK to Press Release: http://www.prnewswire.com/news-releases/lifeline-biotechnologies-receives-third-software-patent-170071356.html

3) In September 2014, First Warning Systems Changes Name to Cyrcadia Health

LINK: http://cyrcadiahealth.com/first-warning-systems-changes-name-to-cyrcadia-health/

4) Business Partner with AMS (Advanced Medical System): http://www.amssg.com/AMS/PR_2014_files/CHI_Press%20Release_031014.pdf

5) Cyrcadia Health Website LINK: http://cyrcadiahealth.com/core-technology/


RECENT NEWS : http://finance.yahoo.com/news/lifeline-biotechnologies-llbo-q1-2015-171609507.html

LLBO History + Website LINK: http://www.lbti.com/#!info/c4nz

Quote From Afforementioned Press Release: :

" LLBO's primary asset is its investment in Cyrcadia Inc. (Cyrcadia). That investment is achieving meaningful added value as Cyrcadia prepares to enter the final clinical trials that will be conducted at El Camino Hospital (ECH) in Mountain View, CA and the Ohio State University (OSU) Oncology Hospital in Columbus, OH. The trials have been approved through Investigational Review Boards (IRB's) of ECH and are currently undergoing the review process at OSU. The ECH trial is slated for start before the end of April 2015. The trials are expected to be completed in four to 6 months. On completion Cyrcadia will obtain CE Marking allowing for sales and marketing outside of the USA. On completion of the trials Cyrcadia will be submitting a 510(k) to the FDA. Post clearance, marketing will begin in the USA. International sales are expected in Q4 of 2015 and US sales in Q1 or Q2 of 2016"


INDEPENDENT PRIMARY MARKET RESEARCH VALUATION AND EXECUTIVE SUMMARY MUST READ:

http://quoi.info/wp-content/uploads/2012/10/executive-summary.pdf


5) Stanford University Canary Center for Early Cancer Detection has pledged $187,000 to help fund the equipment for the trials at El Camino Hospital.

LINK To Press Release: http://www.otcmarkets.com/stock/LLBO/news/Lifeline-Biotechnologies--LLBO--Q1-2015-Update?id=99373&b=y



6 )Detected, a documentary movie about the journey to market of the iTBra™ was commissioned and paid for by Cisco Systems and will premiere at the SxSW Technology and Film Festival in Austin Texas next week, 3/16/15.

LINK TO AMAZING DETECTED TRAILER: http://newsroom.cisco.com/video-content?type=webcontent&articleId=1611072

LINK To Detected Movie Site: http://detectedmovie.com

7) CISCO is Promoting the Hell out of Cyrcadia and it's Breakthrough iTBra

CISCO YOUTUBE VIDEO:

LINK TO CISCO TWEETS ABOUT CIRCADIA AND THE MOVIE DETECTED (470K FOLLOWERS):

https://twitter.com/Cisco/status/577511348424167424
https://twitter.com/detectedmovie/status/577541555449364480
https://twitter.com/Cisco/status/577546373572239360



8) LINK TO CYRCADIA'S RESEARCH AND DEVELOPMENT TEAM FEATURNG TOP 1% SURGEON IN WORLD + STANFORD GRADS: cyrcadiahealth.com/medical-advisory-board/

CYRCADIA BREAST-CANCER PREVENTION DEVICE CLINICAL TRIAL RESULTS:

LINK: http://cyrcadiahealth.com/core-technology/

Over 500 women tested in previous clinical trials achieved promising results in sensitiy and accuracy at 87% correlation to cancer, when compared to mammography’s 83% correlation. The studies also indicated improved outcomes for the Cyrcadia Health solution in difficult to image (dense breast tissue) patient populations. Cyrcadia Health is preparing for a multi-site final validation clinical study to be conducted in leading US and Asia cancer hospitals in late 2014. Cyrcadia Health intends to show equal to improved results to mammography in the general population with improved results over todays “gold standards” in the dense tissue population, which entails over 60% of all women under, and 40% over the age of 40. Our comfortable, non-compressive and non-irradiative approach will help to populate a global “big data” core library on phenotype/genotype, and demographic variables contributing to the state of breast cancer on a worldwide basis.


MORE EFFECTIVE THAN THE MODERN DAY TREATMENT AND BENEFICIAL EARLY DETECTION ASPECT + COST EFFECTIVE

THE TECHNOLOGY SAVES CONSUMERS AND MEDICAL INSURANCES MONEY:

The Cyrcadia Health solution is a cost effective system that through early screening and detection can improve patient outcomes, reduce healthcare costs, improve surgical decision processes, and is a patient-friendly solution for breast screening.

Doctors Weigh in LINK: http://thedoctorweighsin.com/cyrcadia-health-wearable-social-breast-cancer-screening-bra/


9) FLEXTRONICS ($7BILLION DOLLAR COMPANY) IS INVESTED IN CYRCADIA'S REVOLUTIONARY PRODUCT AND IS MANUFACTURING THE ITBRA: https://gigaom.com/2015/02/10/heres-a-cancer-detecting-bra-thats-better-than-a-mammogram/



"The product looks like a sports bra and will eventually hold a grid-like mesh of sensors, manufactured by Flextronics, inside the fabric.

iTbra is getting a boost via a documentary film backed by Cisco, which will be shown at SXSW Film in Austin, Texas next month. Cisco is getting involved because it hopes to build a big business helping old-line companies understand how to bring technology into their day-to-day operations. "


CYRCADIA HEALTH SOLUTIONS PARTNERS LINK: http://cyrcadiahealth.com/partners/

FLEXTRONICS CEO INTERVIEW REVEALS IT ALL (SKIP TO 5:50 IF IN RUSH):

10) The ECH trial is slated for start before the end of April 2015.

The trials are expected to be completed in four to 6 months. On completion Cyrcadia will obtain CE Marking allowing for sales and marketing outside of the USA. On completion of the trials Cyrcadia will be submitting a 510(k) to the FDA. Post clearance, marketing will begin in the USA.

It is interesting to note that Dr. Farrar at OSU will be the primary investigator for the trials conducted at OSU. Dr. Farrar headed the original "proof of concept" study that was conducted at OSU. Dr. Farrar published on the results of this study, commenting on the potential of this lifesaving technology that could assist in the early detection of breast tissue abnormalities and breast cancers.

LINK TO AFFOREMENTIONED QUOTES: http://www.marketwired.com/press-release/lifeline-biotechnologies-llbo-q1-2015-update-otc-pink-llbo-1999978.htm

CYRCADIA HEALTH FEATURED ON ABC 7: http://cyrcadiahealth.com/abc-7-news-video/

OTC SHORT REPORT LINK : http://otcshortreport.com/index.php?index=LLBO#.VQeb5V6LQds

BARCHART TRADER'S CHEAT SHEET: http://www.barchart.com/cheatsheet.php?sym=LLBO

LLBO Share Structure: http://www.otcmarkets.com/stock/LLBO/profile

650m FLOAT


GLTA